Computer-aided detection (CAD) firm iCAD of Nashua, NH, reported growth in revenues and a lower net loss for the company's second quarter (end-June 30).
For the period, iCAD posted sales of $6.1 million, up 7% compared to sales of $5.7 million in the same period of 2009. The company's net loss for the quarter was $736,000, compared with a net loss of $1.4 million in the corresponding quarter of 2009.
For the six months to date, iCAD has posted revenue of $12.6 million, down 2% compared to sales of $12.9 million in the first six months of 2009. The company's net loss so far this year is $1.9 million, compared with a net loss of $2.4 million at the same point last year.
The company said it has seen signs of stabilization in the U.S. market, with consistent demand for digital mammography CAD software compared to the first quarter of the year. iCAD expects continued improvement in the second half of 2010 as one of its major OEM partners is awaiting U.S. Food and Drug Administration (FDA) clearance for a new digital mammography system, and was only able to ship a small quantity of its older system in the quarter.
Related Reading
iCAD debuts new MRI software, July 20, 2010
iCAD wins government contract, June 10, 2010
iCAD to launch CTC CAD software, May 27, 2010
iCAD revenue slips in Q1, April 29, 2010
iCAD supports educational sessions, March 16, 2010
Copyright © 2010 AuntMinnie.com
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
